Abstract Number: 2747 • 2016 ACR/ARHP Annual Meeting
Dapsa-28 May be Used Instead of Dapsa-66/68 in Psoriatic Arthritis
Background/Purpose: Disease Activity index for Psoriatic Arthritis (DAPSA) originally developed from patients with reactive arthritis and validated in psoriatic arthritis (PsA) patients. DAPSA includes…Abstract Number: 543 • 2016 ACR/ARHP Annual Meeting
Synovial Features of Rheumatoid Arthritis and Psoriatic Arthritis Differ in Patients in Clinical and Ultrasound Remission after Anti-TNF Therapy
Background/Purpose: Persistent disease remission is the major goal of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) treatment. The combined use of clinical and ultrasound selection…Abstract Number: 1703 • 2016 ACR/ARHP Annual Meeting
Early Onset of Efficacy with Apremilast Monotherapy in Biologic-Naive Patients with Active Psoriatic Arthritis: A Phase IIIb, Randomized, Controlled Trial
Background/Purpose: ACTIVE is the first apremilast (APR) trial that evaluated time to onset of efficacy beginning at Wk 2 in psoriatic arthritis (PsA) patients (pts)…Abstract Number: 2930 • 2016 ACR/ARHP Annual Meeting
Specific Metabolic and Functional Changes in Peripheral CD8+ T Cells Specifically Distinguish RA from PSA and SPA
Background/Purpose: Studies by our team and others have shown that CD8 T cells (CD8s) in RA have a pro-inflammatory, cytotoxic effector phenotype and may, therefore,…Abstract Number: 629 • 2016 ACR/ARHP Annual Meeting
Golimumab Improves Patient-Reported Outcomes and Socio- and Health-Economic Parameters in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS): Results from a Non-Interventional Clinical Evaluation in Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various randomized clinical trials with patients eligible for clinical studies. Data from patient-reported outcomes (PROs)…Abstract Number: 1711 • 2016 ACR/ARHP Annual Meeting
Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials
Background/Purpose: Of the multiple manifestations of psoriatic arthritis (PsA), enthesitis and dactylitis are hallmark features that affect many patients (pts), can lead to pain and…Abstract Number: 2983 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, or Adalimumab in Patients with Active Psoriatic Arthritis and an Inadequate Response to Conventional Synthetic Dmards: A Randomized, Placebo‑Controlled, Phase 3 Trial
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of psoriatic arthritis (PsA). This study evaluated tofacitinib efficacy and safety vs placebo…Abstract Number: 930 • 2016 ACR/ARHP Annual Meeting
How to Implement Cardiovascular Disease Risk Assessment for Patients with Inflammatory Joint Diseases in Daily Rheumatology Practice: An Overview of a Nationwide Norwegian Project
Background/Purpose: The EULAR recommendations for cardiovascular disease (CVD) risk management in patients with inflammatory joint diseases (IJD) states that CVD risk assessment should be considered…Abstract Number: 1713 • 2016 ACR/ARHP Annual Meeting
Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, acts to regulate immune activity in psoriatic arthritis (PsA) patients. PALACE 1 (NCT01172938), 2 (NCT01212757), and 3…Abstract Number: 3085 • 2016 ACR/ARHP Annual Meeting
Do Depression and Anxiety Reduce the Chance of Remission in Rheumatoid Arthritis and Psoriatic Arthritis?
Background/Purpose: Depression and anxiety are reported to predict poorer treatment outcomes in rheumatoid arthritis (RA).1 Whether this can be confirmed in larger, prospective studies as…Abstract Number: 938 • 2016 ACR/ARHP Annual Meeting
Prevalence of Non-Radiographic Axial Spondyloarthritis in Psoriatic Arthritis – a Single Center Observational Study
Background/Purpose: Sacroiliitis, as detected by plain radiographs of the sacroiliac joints (SIJ), has been reported in a third of the psoriatic arthritis (PsA) population. (1)…Abstract Number: 1722 • 2016 ACR/ARHP Annual Meeting
Predictors of Achieving Remission Among Patients with Psoriatic Arthritis Prescribed TNF Inhibitors
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease with varied response to therapy. We examined predictors of remission at one year among patients with PsA…Abstract Number: 961 • 2016 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial
Background/Purpose: Secukinumab, an anti–interleukin-17A monoclonal antibody, provided rapid and significant improvements in the key clinical domains of psoriatic arthritis (PsA) in the FUTURE 1 study…Abstract Number: 1728 • 2016 ACR/ARHP Annual Meeting
Comparison of Adherence to Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis and Other Rheumatic Disease
Background/Purpose: Psoriatic arthritis (PsA), Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are an inflammatory arthritis causing joint damage and disability. Non-adherence to disease modifying anti-rheumatic…Abstract Number: 1326 • 2016 ACR/ARHP Annual Meeting
Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthropathy, Following Lyme Disease
Background/Purpose: Lyme arthritis (LA) usually responds to antibiotic therapy, though immune-mediated synovitis may persist after antibiotic treatment, usually confined to a previously infected joint,…
- « Previous Page
- 1
- …
- 70
- 71
- 72
- 73
- 74
- …
- 81
- Next Page »